Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 13/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.50 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960323 | 0.88 | DYRK1A (0.63) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3510112 | 0.81 | TDP1 (0.62) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3506427 | 0.81 | CDK1 (0.66) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL13072058 | 0.79 | KDM4E (0.60) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL13071846 | 0.78 | TDP1 (0.55) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL26354676 | 0.76 | CDK1 (0.65) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL14964187 | 0.75 | CDK1 (0.59) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL14977880 | 0.75 | CCNE2 (0.60) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL13030941 | 0.75 | TDP1 (0.52) | TDP1KDM4ENPC1MAPTCDK1 | |
| SCHEMBL3507494 | 0.74 | CDK1 (0.43) | TDP1KDM4ENPC1MAPTCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450342-B2 | Perharidines as CDK inhibitors | CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450342-B2 | Perharidines as CDK inhibitors | CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450342-B2 | Perharidines as CDK inhibitors | CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20100280065-A1 | PERHARIDINES AS CDK INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-04 | — | — | US | disclosed |
| US-20100280065-A1 | PERHARIDINES AS CDK INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-04 | — | — | US | disclosed |
| WO-2009034411-A1 | PERHARIDINES AS CDK INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034475-A2 | PERHARIDINES AS CDK INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280065-A1 | PERHARIDINES AS CDK INHIBITORS | CDK4, CDK9, CDK7 | TDP1 351/4885KDM4E 66/4885NPC1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.